Novo Nordisk A/S $NVO Shares Purchased by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 11.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 631,405 shares of the company’s stock after purchasing an additional 66,398 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $32,126,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Sigma Planning Corp increased its position in Novo Nordisk A/S by 16.5% during the fourth quarter. Sigma Planning Corp now owns 6,557 shares of the company’s stock worth $333,000 after purchasing an additional 927 shares during the last quarter. Laurel Wealth Advisors LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $164,000. Trifecta Capital Advisors LLC increased its position in Novo Nordisk A/S by 162.3% during the fourth quarter. Trifecta Capital Advisors LLC now owns 1,616 shares of the company’s stock worth $82,000 after purchasing an additional 1,000 shares during the last quarter. W.G. Shaheen & Associates DBA Whitney & Co increased its position in Novo Nordisk A/S by 10.1% during the fourth quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 262,783 shares of the company’s stock worth $13,370,000 after purchasing an additional 24,037 shares during the last quarter. Finally, GC Wealth Management RIA LLC increased its position in Novo Nordisk A/S by 26.0% during the fourth quarter. GC Wealth Management RIA LLC now owns 25,533 shares of the company’s stock worth $1,299,000 after purchasing an additional 5,266 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $42.24 on Friday. The company has a market capitalization of $188.58 billion, a PE ratio of 12.17, a price-to-earnings-growth ratio of 9.57 and a beta of 0.73. The firm has a fifty day simple moving average of $38.50 and a 200-day simple moving average of $47.33. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.34 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were paid a $1.2751 dividend. The ex-dividend date was Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is 50.43%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on NVO shares. CICC Research started coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective for the company. Wolfe Research started coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Finally, Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA proposal to bar bulk compounding of GLP?1 active ingredients would limit lower?cost copycats and protect branded sales, a direct near?term win for Novo Nordisk’s Ozempic/Wegovy franchise. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Novo is advancing an oral formulation of Ozempic and pursuing pediatric approvals — expansions that could broaden addressable markets beyond injectables and extend lifecycle revenue if approved. Novo Nordisk Expands GLP-1 Reach With Oral Ozempic And Pediatric Push
• Positive Sentiment: Market commentary (CNBC/Fast Money) and momentum investors are viewing NVO’s lower price as a buying opportunity versus peers, supporting demand for the stock after the pullback. Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%
• Neutral Sentiment: Novo and Lexicon started a Phase 1 study for LX9851 (oral, non?incretin obesity candidate) — early?stage collaboration that could add long?term optionality but won’t move near?term revenue. Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851
• Neutral Sentiment: Analysts show mixed but modestly constructive stance (Erste raised small EPS estimates; consensus price target around $65.56), offering context that some sellside models still see upside from here. Novo Nordisk A/S (NYSE:NVO) Receives $65.56 Average Price Target from Analysts
• Negative Sentiment: Canada approved Dr. Reddy’s generic version of Ozempic — a precedent for regulatory openings and pricing pressure in markets that could compress margins over time. Canada Approves Dr. Reddy’s Generic Version of Novo Nordisk’s Ozempic
• Negative Sentiment: Competitive and margin risks persist: Eli Lilly’s retatrutide showed surgery?level weight loss in trials and industry commentary flags ongoing price competition and margin compression for GLP?1s. These are material long?term threats to volume and pricing. Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started
• Negative Sentiment: Bull/bear media commentary (e.g., Jim Cramer) warns Novo could lose share to Lilly’s oral pill strategy — a sentiment headwind that can exacerbate selling in volatile sessions. Jim Cramer Believes “Novo Nordisk Is Going to Lose a Lot of Share on the Pill to Eli Lilly”

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.